Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 5;26(10):5955–5966. doi: 10.1038/s41380-021-01045-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — A Relationship of plasma tau and NfL to number of days from death in sporadic CJD, in cross-sectional dataset (earliest available sample from each patient; n = 231—left panels) and longitudinal dataset (all samples from patients with more than one available; n = 114 samples from 47 individuals—right panels). Red continuous, dashed and dotted lines show 50th, 75th and 90th centiles of healthy controls respectively. Blue lines on the longitudinal charts show the linear mixed effects model fits for each individual (see text). Patients with very rapidly progressive disease, typically enrolled to the Cohort at a late stage of disease, are less likely to have more than one blood sample available, so are under-represented in the longitudinal sample set. B Relationship of plasma tau and NfL to measures of disease progression in sporadic CJD. Left panels show biomarkers (log scale) plotted against MRC Scale, which measures severity of functional impairment. Right panels show biomarkers (log scale) plotted against MRC Slope, which provides a measure of the rate of clinical progression. The earliest sample from each patient with necessary data available is included. As MRC Slope cannot be modelled for patients with a baseline MRC Scale < 5, fewer patients are represented in MRC Slope charts, and the missing cases are skewed towards those enrolled at an advanced stage of disease, and those with very rapid clinical progression.